Acute transient hepatocellular injury in cholelithiasis and cholecystitis without evidence of choledocholithiasis

Table 2 Liver tests in patients with cholelithiasis and cholecystitis who underwent cholecystectomy

Variable (normal range)	CBD stones (90)		No CBD stones (96)		P-value1
	mean ± SD (range)	Incidence of abnormal results	mean ± SD (range)	Incidence of abnormal results
AST (5-35 IU/L)	137.2 ± 131.8 (19-693)	84.40% (76/90)	62.9 ± 96.9 (10-670)	41.67% (40/96)	< 0.001
ALT (5-30 IU/L)	178.7 ± 159.0 (17-696)	95.55% (86/90)	83.8 ± 109.5 (12-566)	51.04% (49/96)	< 0.001
ALK-P (40-133 IU/L)	204.7 ± 122.7 (14-672)	71.11% (64/90)	118.8 ± 92.5 (38-615)	22.92% (22/96)	< 0.001
D. Bilirubin (0.0-0.4 mg/dL)	2.16 ± 2.08 (0.1-12)	88.89% (80/90)	0.64 ± 1.01 (0-5.0)	32.29% (31/96)	< 0.001
T. Bilirubin (0.2-1.3 mg/dL)	3.81 ± 3.27 (0.3-18.6)	76.67% (69/90)	1.50 ± 1.68 (0.2-9.3)	27.08% (26/96)	< 0.001

¹Statistical analysis using the Student’s t-test. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALK-P: Alkaline phosphatase; D.: Direct; T.: Total.